Marta Gurrea Soteras

Dr. Marta Gurrea Soteras


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
JSJavier Monleón Sancho
Javier Monleón Sancho
VSVerónica Serrano-de-la-Cruz-Delgado
Verónica Serrano-de-la-Cruz-Delgado
MVMaria José Nuñez Valero
Maria José Nuñez Valero
MSMarta Gurrea Soteras
Marta Gurrea Soteras
VAVicente Payá Amate
Vicente Payá Amate
ACAntonio Abad Carrascosa
Antonio Abad Carrascosa

22 February 2025 in Cancers
Verified
Journal Article
Open access
PDF file
ABAlexandra Trelis Blanes
Alexandra Trelis Blanes
VLVíctor Lago
Víctor Lago
RMRosario Pérez Martínez
Rosario Pérez Martínez
VRVicente Belloch Ripollés
Vicente Belloch Ripollés
GMGuillermina Montoliu
Guillermina Montoliu
SDSantiago Domingo
Santiago Domingo
Introduction: The maximum residual tumour size after surgery is the most important prognostic factor related to survival in advanced ovarian cancer. This parameter can be subjectively determined by the surgeon at the end of the operation and by a radiologist with a postoperative CT scan. CT scans after optimal cytoreduction can reveal residual/progressive disease in a significant percentage of patients, ranging from 21% to 49%. The aim of this study was to validate the PCI scale for the systematic reading of postoperative CT scans in patients with advanced ovarian cancer and to establish it as a new prognostic marker. Material and Methods: Patients with advanced ovarian cancer (FIGO II-IV), diagnosed between 2007 and 2019 in Hospital La Fe Valencia, in whom cytoreductive surgery was performed (achieving R0 or R1), and in whom a postoperative CT scan was performed between the third and eighth week post-surgery and prior to the start of chemotherapy, were included. Two different radiologists who specialised in gynaecological malignancy performed a blind analysis of the CT scans. They then read the images using the Peritoneal Carcinomatosis Index (PCI) scale, which divides the abdominopelvic cavity into 12 quadrants. Using the Qualitative Assessment (QA) scale, they established the presence or lack of tumour disease in each of these regions, with QA 1–2 being definitely/probably normal, QA 3 indeterminate and QA 4–5 probably/definitely metastatic. Results: This study included a cohort of 117 patients. The radiological study found measurable tumour disease in up to 49% of patients after optimal primary cytoreduction (R0 or R1). There was “substantial agreement” between the results of the two radiologists according to the Kappa analysis (0.624). Both radiologists’ (A and B) findings were related to a significant reduction in both disease-free survival (DFS) and overall survival (OS) in patients with residual disease in the CT scan (QA 4–5) versus those without macroscopic disease (QA 1–3) (p < 0.05). Conclusions: The finding of radiological tumour disease on a standardised and systematised postsurgical CT scan prior to the initiation of adjuvant chemotherapy is associated with the prognosis of patients with advanced ovarian cancer.

5 March 2025 in Journal of Lower Genital Tract Disease
Verified
Journal Article
Closed access
MCMarta Arnáez de la Cruz
Marta Arnáez de la Cruz
AMAnna Martin Marti
Anna Martin Marti
SFStela Álvarez Fernandez
Stela Álvarez Fernandez
MSMarta Gurrea Soteras
Marta Gurrea Soteras
MGMaria Dolores Apt Comes García
Maria Dolores Apt Comes García
MRMireya Prieto Rodríguez
Mireya Prieto Rodríguez
Objectives: This study evaluates a new vaginal self-sampling device for high-risk human papillomavirus (HR-HPV) detection compared to clinician-collected samples using real-time polymerase chain reaction (PCR). Methods: A total of 345 women aged between 23 and 72 were enrolled in this study. After receiving information about the study, women were provided with a vaginal collecting device to collect self-sample, and then a medical professional collected the cervical sample. All the clinician-collected samples were processed using the Cobas 4800 HPV assay, and the self-samples were processed with the automated MAIS extraction system. These results were used to compare the new device's performance to the clinician-collected cervical samples. All the clinician-collected samples were also analyzed with a new HPV screening assay to compare the performance of this assay on 2 different types of samples. Results: Overall agreement for detecting any HR-HPV between clinician-collected samples and self-samples was 93.7% with a Cohen κ coefficient of 0.842. As both assays allow to identify genotypes 16, 18 and to detect the same 12 HR-HPV genotypes in a pool, the authors analyzed the agreement between self- and clinician-collected samples by genotypes and it was shown to be also excellent for HPV16 and the pool of other HR-HPV. Conclusions: This self-sampling device has demonstrated detection rates that are comparable to those of samples collected by clinicians.